查看購物車
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1931243

植入式冠狀動脈藥物洗脫支架市場（依藥物類型、代數、聚合物類型、支架材料及適應症分類），全球預測，2026-2032年

Implantable Coronary Drug Eluting Stent Market by Drug Type, Generation, Polymer Type, Stent Material, Indication - Global Forecast 2026-2032
出版日期: | 出版商: 360iResearch | 英文 186 Pages | 商品交期: 最快1-2個工作天內

價格

※ 本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

預計到 2025 年，植入式冠狀動脈藥物釋放型支架市場價值將達到 83.5 億美元，到 2026 年將成長至 87.1 億美元，到 2032 年將達到 121.6 億美元，複合年成長率為 5.51%。

關鍵市場統計數據
基準年 2025 83.5億美元
預計年份：2026年 87.1億美元
預測年份 2032 121.6億美元
複合年成長率 (%) 5.51%

策略介紹：臨床緊迫性、材料科學的進步以及法規環境為推動植入式冠狀動脈藥物釋放型支架的創新和廣泛應用提供了框架。

本執行摘要旨在就植入式冠狀動脈藥物釋放型支架展開策略對話，重點在於臨床需求、器械工程和商業性動態的交匯點，以指導產品策略和相關人員的決策。降低血管再阻塞和改善長期血管通暢性的干涉措施仍然是冠狀動脈疾病治療的重中之重，推動著支架藥理學、聚合物科學和支架結構方面的不斷改進。隨著技術的融合，臨床醫生和醫療保健系統優先考慮的是持續的臨床療效、易於實施以及與不斷發展的抗血小板療法的兼容性，這些因素將影響採購和應用路徑。

分析重塑治療模式的變革性轉變：設備小型化、生物可吸收平台、精準藥物治療和整合數位診斷技術

冠狀動脈藥物釋放型支架領域正經歷著由技術、臨床和監管因素驅動的變革，重新定義了產品藍圖和臨床實踐。微型化和精細化的支架幾何結構提高了支架在複雜解剖結構中的輸送性和貼合性，而抗增殖藥物和靶向釋放動力學的進步則減少了晚期管腔丟失，並使血管癒合更加可預測。同時，生物可吸收支架和混合支架策略的整合正在推動對長期支架與臨時血管支架的評估，這將影響抗血小板治療的持續時間和追蹤影像通訊協定。

評估2025年美國關稅政策變化對供應鏈、成本結構、製造策略和國際採購趨勢的累積影響

美國關稅調整將於2025年生效，其累積影響將波及整個植入式冠狀動脈藥物釋放型支架價值鏈，影響原料採購、組件製造及最終組裝策略。關稅相關的成本壓力將促使製造商重新評估其供應商組合，並探索近岸外包和區域內生產，以應對貿易波動並縮短前置作業時間。因此，採購團隊必須權衡供應鏈本地化帶來的經濟效益與建立符合規範的製造地、檢驗流程和認證供應路線所需的營運複雜性和投資，以滿足嚴格的品質和監管要求。

整合藥物類型、世代週期、聚合物和材料選擇以及臨床適應症等關鍵細分洞察，以揭示產品定位和臨床差異化優勢。

詳細的市場區隔分析闡明了產品設計與臨床應用如何交匯融合，為器材開發商和臨床醫生創造差異化的價值提案。基於藥物類型，本研究檢視了依Everolimus洗脫支架、Sirolimus洗脫支架、西羅莫司洗脫支架和佐他莫司洗脫支架的市場狀況。每種類型的藥物都具有獨特的藥物動力學特徵、組織相容性考慮以及影響臨床選擇的歷史療效數據。這些藥物差異與器械的世代更迭相互作用。從第一代到第二代再到第三代產品的演進反映了聚合物技術、支架梁厚度和輸送系統的改進，這些改進共同影響器械的安全性和傳輸性能。

整合美洲、歐洲、中東和非洲以及亞太地區的趨勢，重點關注市場准入的採用趨勢、報銷壓力和在地化策略

區域趨勢將對冠狀動脈藥物釋放型支架的應用模式、報銷途徑和市場推廣策略產生深遠影響。在美洲，醫療系統越來越重視比較臨床證據和成本效益分析，以支持採購決策，集中採購和打包支付模式正在影響醫院的採購決策和術後照護路徑。因此，在該地區運營的製造商必須優先建立可靠的臨床註冊研究和真實世界證據，以滿足基於價值的採購要求，並證明其能夠降低再入院率和再次手術率。

競爭格局洞察，重點介紹領先設備製造商的策略組合、研發軌跡、夥伴關係模式和商業化路徑

冠狀動脈藥物釋放型支架市場的主要企業透過持續的研發投入、策略聯盟以及不斷累積的臨床證據來凸顯其優勢，這些證據支持其卓越的手術效果和長期安全性。競爭優勢越來越依賴能夠證明其在輸送性、晚期不利事件發生率和手術流程簡化方面取得實際改進，從而降低醫療總成本。因此，各機構正將資源投入到薄支架設計、新型合金和最佳化藥物-聚合物基質的研發中，同時與學術機構合作，並透過研究者主導的臨床試驗和註冊研究加速證據的累積。

針對產業領導者的具體策略建議：重點在於監管合規、價值鏈韌性、臨床證據產生和基於價值的商業化策略。

行業領導者必須制定一套連貫的策略，將技術創新與切實可行的商業化和監管計劃相結合。首先，他們應優先產生臨床證據，這些證據既要涵蓋隨機對照試驗的終點指標，也要涵蓋真實世界的療效指標。這種雙管齊下的方法將有助於完善監管申報和與支付方的溝通，同時為差異化產品標籤和臨床醫生採納提供參考。其次，他們應透過多元化合格供應商、評估區域或聯合生產夥伴關係以及實施流程自動化來增強供應鏈韌性，從而降低關稅和物流波動帶來的風險。這些措施將降低營運風險，並確保高需求設施的穩定供應。

嚴謹的調查方法概述：詳細介紹資料來源、相關人員訪談、臨床文獻綜合以及為確保研究結果的可靠性而採用的分析架構。

我們的調查方法結合了系統性的文獻回顧、與關鍵相關人員的直接對話以及結構化的分析框架，以確保獲得嚴謹且切實可行的見解。我們首先對同行評審的臨床研究、監管指導文件和技術白皮書進行了全面審查，以梳理現有證據基礎並識別安全性和有效性數據方面的不足。在此基礎上，我們設計了與各類相關人員，包括介入性心臟病專家、臨床負責人、採購主管和生產專家，以提供關於流程需求、實施障礙和營運重點的定性觀點。

一份權威的綜合分析報告，重點闡述了塗藥支架的臨床益處、技術進步、監管影響以及持續發展的戰略要務。

這個結論綜合了分析中湧現的核心訊息：藥物選擇、聚合物設計和支架結構方面的技術進步正在顯著改善支架的輸送性和癒合效果；監管機構和支付方越來越要求提供全面的臨床證據和清晰的價值證明；供應鍊和地緣政治因素，包括關稅變化，正在重塑生產和籌資策略。這些趨勢要求採用嚴謹的產品開發方法，將臨床檢驗、業務永續營運和最佳化的市場進入計畫結合。

目錄

第1章：序言

第2章調查方法

  • 研究設計
  • 研究框架
  • 市場規模預測
  • 數據三角測量
  • 調查結果
  • 調查前提
  • 調查限制

第3章執行摘要

  • 首席體驗長觀點
  • 市場規模和成長趨勢
  • 2025年市佔率分析
  • FPNV定位矩陣，2025
  • 新的商機
  • 下一代經營模式
  • 產業藍圖

第4章 市場概覽

  • 產業生態系與價值鏈分析
  • 波特五力分析
  • PESTEL 分析
  • 市場展望
  • 上市策略

第5章 市場洞察

  • 消費者洞察與終端用戶觀點
  • 消費者體驗基準
  • 機會地圖
  • 分銷通路分析
  • 價格趨勢分析
  • 監理合規和標準框架
  • ESG與永續性分析
  • 中斷和風險情景
  • 投資報酬率和成本效益分析

第6章：美國關稅的累積影響，2025年

第7章：人工智慧的累積影響，2025年

第8章 依藥物類型植入式冠狀動脈藥物洗脫支架市場

  • Everolimus洗脫
  • 紫杉醇洗脫
  • Sirolimus洗脫
  • 佐他莫司洗脫

第9章 依世代分類的植入式冠狀動脈藥物洗脫支架市場

  • 第一代
  • 第二代
  • 第三代

第10章 依聚合物類型分類的植入式冠狀動脈藥物洗脫支架市場

  • 可生物分解聚合物
  • 耐用聚合物
  • 不含聚合物

第11章 依支架材質分類的植入式冠狀動脈藥物洗脫支架市場

  • 鈷鉻
  • 鉑金鉻
  • 不銹鋼

第12章植入式冠狀動脈藥物洗脫支架市場（依適應症分類）

  • 多支血管疾病
  • 非ST段抬高型心肌梗塞
  • ST段上升型心肌梗塞
  • 穩定性心絞痛

第13章植入式冠狀動脈藥物洗脫支架市場（依地區分類）

  • 美洲
    • 北美洲
    • 拉丁美洲
  • 歐洲、中東和非洲
    • 歐洲
    • 中東
    • 非洲
  • 亞太地區

第14章植入式冠狀動脈藥物洗脫支架市場（依類別分類）

  • ASEAN
  • GCC
  • EU
  • BRICS
  • G7
  • NATO

第15章 各國植入式冠狀動脈藥物洗脫支架市場

  • 美國
  • 加拿大
  • 墨西哥
  • 巴西
  • 英國
  • 德國
  • 法國
  • 俄羅斯
  • 義大利
  • 西班牙
  • 中國
  • 印度
  • 日本
  • 澳洲
  • 韓國

16. 美國植入式冠狀動脈藥物洗脫支架市場

第17章：中國植入式冠狀動脈藥物洗脫支架市場

第18章 競爭格局

  • 市場集中度分析，2025年
    • 濃度比（CR）
    • 赫芬達爾-赫希曼指數 (HHI)
  • 近期趨勢及影響分析，2025 年
  • 2025年產品系列分析
  • 基準分析，2025 年
  • Abbott Laboratories
  • Alvimedica Medical Technologies Inc.
  • B. Braun Melsungen AG
  • Biosensors International Group, Ltd.
  • Biotronik SE & Co. KG
  • Boston Scientific Corporation
  • Concept Medical, Inc.
  • Cook Medical Incorporated
  • Hexacath SAS
  • Lepu Medical Technology（Beijing）Co., Ltd.
  • Medinol Ltd.
  • Medtronic plc
  • Meril Life Sciences Pvt. Ltd.
  • MicroPort Scientific Corporation
  • OrbusNeich Medical Group
  • REVA Medical, Inc.
  • Sahajanand Medical Technologies Ltd.
  • SINOMED Co., Ltd.
  • Terumo Corporation
  • Translumina GmbH
Product Code: MRR-7B550E008DDF

The Implantable Coronary Drug Eluting Stent Market was valued at USD 8.35 billion in 2025 and is projected to grow to USD 8.71 billion in 2026, with a CAGR of 5.51%, reaching USD 12.16 billion by 2032.

KEY MARKET STATISTICS
Base Year [2025] USD 8.35 billion
Estimated Year [2026] USD 8.71 billion
Forecast Year [2032] USD 12.16 billion
CAGR (%) 5.51%

Strategic introduction framing the clinical urgency, material science advances, and regulatory environment driving implantable coronary drug eluting stent innovation and adoption

This executive summary opens a strategic conversation about implantable coronary drug eluting stents, emphasizing the intersection of clinical need, device engineering, and commercial dynamics that inform product strategy and stakeholder decision-making. Coronary artery disease management continues to prioritize interventions that reduce restenosis and improve long-term vessel patency, driving ongoing refinement in stent pharmacology, polymer science, and scaffold architecture. As technologies converge, the priorities for clinicians and health systems include durable clinical outcomes, ease of deployment, and compatibility with evolving antiplatelet regimens, which together shape procurement and adoption pathways.

Transitioning from clinical imperatives to market realities, the introduction frames why manufacturers, payers, and provider networks must adapt to a landscape where incremental innovation yields meaningful differences in patient management. In addition, regulatory scrutiny and post-market surveillance expectations are intensifying, prompting device developers to generate robust real-world evidence and to articulate clear value propositions to payers. Consequently, strategic planning for next-generation stent platforms demands an integrated view across R&D, clinical affairs, reimbursement strategy, and supply chain resilience to ensure timely adoption and sustained clinical benefit.

Analysis of transformative shifts including device miniaturization, bioresorbable platforms, precision pharmacotherapy, and integrated digital diagnostics reshaping treatment paradigms

The landscape for coronary drug eluting stents is experiencing transformative shifts driven by technological, clinical, and regulatory forces that are redefining product roadmaps and clinical practice. Miniaturization and refinement of scaffold geometries have improved deliverability and conformability in complex anatomies, while advances in antiproliferative agents and targeted release kinetics have reduced late lumen loss and provided more predictable vascular healing. Simultaneously, the integration of bioresorbable and hybrid scaffold strategies is prompting reassessment of long-term device residency versus temporary vessel support, with implications for antiplatelet therapy duration and follow-up imaging protocols.

In parallel, material science innovations are accelerating the adoption of alternative alloys and thin-strut designs that balance radial strength with reduced vessel injury. Polymer engineering has evolved from durable coatings to biodegradable matrices and polymer-free approaches to mitigate chronic inflammation and late adverse events. These technical shifts are accompanied by a surge in digital health adjuncts, where implantable devices interface with procedural imaging and data platforms to inform precision deployment and longitudinal outcome tracking. Regulatory pathways are adapting to novel materials and combined-device-drug paradigms, requiring sponsors to engage earlier with authorities and to prioritize clinical evidence that demonstrates both safety and comparative effectiveness. Together, these changes are reshaping competitive positioning, clinical trial design, and commercialization strategies across the ecosystem.

Assessment of the cumulative impact of United States tariff policy changes in 2025 on supply chains, cost structures, manufacturing strategies, and transnational procurement dynamics

The cumulative impact of United States tariff adjustments implemented in 2025 reverberates through the implantable coronary drug eluting stent value chain, influencing raw material sourcing, component manufacturing, and final assembly strategies. Tariff-related cost pressures incentivize manufacturers to reassess supplier portfolios and to explore nearshoring or regional manufacturing to buffer against trade volatility and to shorten lead times. Consequently, procurement teams must balance the economic benefits of supply chain localization with the operational complexity and investment required to establish compliant manufacturing sites, validated processes, and qualified supply streams that meet stringent quality and regulatory expectations.

Moreover, tariff-induced input cost increases can alter pricing negotiations with payers and hospital procurement entities, prompting device makers to bolster their value dossiers with stronger clinical evidence, total cost of care analyses, and clear demonstrations of procedure efficiency. In response, some organizations may pursue strategic partnerships or licensing to distribute manufacturing risk, while others will accelerate automation and process optimization to preserve margin. Cross-border regulatory considerations also intensify as manufacturers reorganize production footprints; this, in turn, requires updated device master files, alignment with customs compliance, and proactive engagement with notified bodies and health authorities. Ultimately, the tariff environment underscores the need for resilient commercial strategies, flexible supply chains, and intensified dialogue with stakeholders to maintain access and continuity of care.

Key segmentation insights integrating drug types, generation cycles, polymer and material choices, and clinical indications to illuminate product positioning and clinical differentiation

A nuanced segmentation analysis clarifies how product design and clinical application intersect to create differentiated value propositions for device developers and clinicians. Based on Drug Type, market is studied across Everolimus Eluting, Paclitaxel Eluting, Sirolimus Eluting, and Zotarolimus Eluting, each of which presents distinct pharmacokinetic profiles, tissue compatibility considerations, and historical performance data that influence clinical preference. These drug distinctions interact with device generation; product evolution from First Generation to Second Generation and onward to Third Generation reflects improvements in polymer technologies, stent strut thickness, and delivery systems that collectively impact safety and deliverability.

Polymer considerations remain central to performance, and segmentation by Polymer Type-Biodegradable Polymer, Durable Polymer, and Polymer Free-captures divergent strategies to balance drug elution control with long-term vessel healing. Stent Material segmentation including Cobalt Chromium, Platinum Chromium, and Stainless Steel highlights trade-offs in radiopacity, radial strength, and manufacturability that inform procedural selection in complex anatomies. Finally, clinical Indication segmentation across Multivessel Disease, Non St Elevation Myocardial Infarction, St Elevation Myocardial Infarction, and Stable Angina maps device attributes to therapeutic need, guiding trial design and labeling strategies. By synthesizing these axes of segmentation, stakeholders can identify where clinical differentiation is most compelling and where incremental improvements translate into meaningful clinical or economic benefit.

Regional dynamics synthesized across Americas, Europe, Middle East & Africa, and Asia-Pacific to reveal adoption trends, reimbursement pressures, and localization strategies for market access

Regional dynamics exert a powerful influence on adoption patterns, reimbursement pathways, and strategic go-to-market approaches for coronary drug eluting stents. In the Americas, health systems emphasize comparative clinical evidence and cost-effectiveness analyses to inform procurement, with centralized group purchasing and bundled payment models shaping hospital purchasing decisions and post-procedural care pathways. Manufacturers operating in this region must therefore prioritize robust clinical registries and real-world evidence generation to satisfy value-based procurement requirements and to demonstrate reduced readmissions and repeat interventions.

Across Europe, Middle East & Africa, regulatory harmonization efforts and varied reimbursement frameworks necessitate tailored market access strategies that reflect local HTA processes, national procurement cycles, and differing hospital infrastructures. In several markets within this region, price negotiation and tendering mechanisms are decisive, making comparative clinical data and procedural efficiency metrics central to success. In the Asia-Pacific region, heterogeneous healthcare maturity and rapidly expanding interventional capacity present substantial opportunities, but they also require nuanced approaches to market entry. Local manufacturing partnerships, regional clinical collaborations, and adaptation of training programs for interventional cardiologists are critical to accelerate adoption. Across all regions, alignment of regulatory submissions, post-market surveillance plans, and clinician education initiatives is essential to translate device innovation into sustained patient impact.

Competitive company landscape insights highlighting strategic portfolios, R&D trajectories, partnership models, and commercialization pathways among leading device manufacturers

Leading companies in the coronary drug eluting stent landscape differentiate through sustained investment in R&D, strategic alliances, and the accumulation of clinical evidence that supports superior procedural outcomes and long-term safety. Competitive positioning increasingly hinges on the ability to demonstrate tangible improvements in deliverability, reduced late adverse events, and simplified procedural workflows that lower the total cost of care. Consequently, organizations are allocating resources to thin-strut designs, alternative alloys, and optimized drug-polymer matrices while partnering with academic centers to accelerate evidence generation through investigator-initiated studies and registries.

In addition to product innovation, commercial strategy has become a vital differentiator. Firms are building integrated service models that include proctoring, simulation-based training, and digital platforms to support procedural planning and outcome monitoring. Strategic collaborations with regional manufacturers, contract development and manufacturing organizations, and specialty suppliers are also prevalent, allowing companies to diversify supply lines and to scale production responsively. Finally, mergers and targeted acquisitions continue to play a role in consolidating complementary technologies and expanding therapeutic portfolios, enabling companies to offer comprehensive interventional solutions that meet evolving clinician and patient needs.

Actionable strategic recommendations for industry leaders focused on regulatory alignment, supply chain resilience, clinical evidence generation, and value-based commercialization strategies

Industry leaders should pursue a cohesive strategy that aligns technological innovation with pragmatic commercialization and regulatory planning. First, prioritize clinical evidence generation that addresses both randomized controlled endpoints and real-world effectiveness measures; this dual approach strengthens regulatory submissions and payer dialogues while delivering insights that support differentiated labeling and clinician adoption. Second, invest in supply chain resilience by diversifying qualified suppliers, evaluating regional manufacturing or co-manufacturing partnerships, and implementing process automation to mitigate tariff and logistics volatility. These measures reduce operational risk and enable more predictable fulfillment for high-volume centers.

Third, adopt a value-based commercialization model that links product claims to procedural efficiency, patient outcomes, and downstream cost reductions. This involves developing robust health economic dossiers, engaging early with HTA bodies, and collaborating with hospitals to pilot bundled care pathways. Fourth, accelerate clinician training and support through immersive simulation, proctorship programs, and integrated data platforms that enhance procedural planning and post-procedural surveillance. Finally, maintain proactive regulatory engagement, anticipating evolving requirements for combination product evaluation and real-world evidence commitments. By implementing these integrated actions, organizations can preserve competitiveness while advancing patient-centered outcomes.

Rigorous research methodology overview detailing data sources, stakeholder interviews, clinical literature synthesis, and analytical frameworks employed to ensure robust findings

The research methodology combines systematic literature synthesis, primary stakeholder engagement, and structured analytical frameworks to ensure rigorous and actionable insights. The approach began with comprehensive review of peer-reviewed clinical studies, regulatory guidance documents, and technical white papers to map the current evidence base and to identify gaps in safety and effectiveness data. This secondary research informed the design of targeted interviews with a cross-section of stakeholders, including interventional cardiologists, clinical trialists, procurement leaders, and manufacturing experts, providing qualitative perspectives on procedural needs, adoption barriers, and operational priorities.

Quantitative inputs were derived from device performance registries, procedural utilization databases, and publicly available regulatory filings to triangulate clinical outcomes and device characteristics. The analysis applied comparative effectiveness frameworks and value-assessment methodologies to evaluate how design features translate into clinical and economic benefits. Throughout the study, the team employed iterative validation, presenting preliminary findings to a panel of clinical advisors and industry stakeholders to refine interpretations and to ensure relevance to real-world decision-making. This transparent and multi-modal methodology underpins the report's recommendations and supports their practical application.

Conclusive synthesis emphasizing clinical benefit, technological momentum, regulatory implications, and strategic imperatives for sustained advancement of drug eluting stents

The conclusion synthesizes the core messages that emerged from the analysis: technological refinements in drug selection, polymer engineering, and scaffold architecture are delivering clinically meaningful improvements in deliverability and healing profiles; regulatory and payer environments increasingly demand comprehensive clinical evidence and clear demonstrations of value; and supply chain and geopolitical forces, including tariff changes, are reshaping manufacturing and procurement strategies. Together, these dynamics call for a disciplined approach to product development that integrates clinical validation, operational resilience, and tailored market access planning.

Looking ahead, successful stakeholders will be those that translate technical innovation into quantifiable clinical and economic benefits, maintain agile manufacturing footprints, and cultivate sustained clinician partnerships that support training and evidence generation. By aligning R&D priorities with payer and provider needs, and by investing in the infrastructure necessary to demonstrate real-world value, organizations can both improve patient outcomes and secure durable market positions. This balanced focus on science, evidence, and commercial execution defines the pathway for long-term success in the evolving implantable coronary drug eluting stent domain.

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Definition
  • 1.3. Market Segmentation & Coverage
  • 1.4. Years Considered for the Study
  • 1.5. Currency Considered for the Study
  • 1.6. Language Considered for the Study
  • 1.7. Key Stakeholders

2. Research Methodology

  • 2.1. Introduction
  • 2.2. Research Design
    • 2.2.1. Primary Research
    • 2.2.2. Secondary Research
  • 2.3. Research Framework
    • 2.3.1. Qualitative Analysis
    • 2.3.2. Quantitative Analysis
  • 2.4. Market Size Estimation
    • 2.4.1. Top-Down Approach
    • 2.4.2. Bottom-Up Approach
  • 2.5. Data Triangulation
  • 2.6. Research Outcomes
  • 2.7. Research Assumptions
  • 2.8. Research Limitations

3. Executive Summary

  • 3.1. Introduction
  • 3.2. CXO Perspective
  • 3.3. Market Size & Growth Trends
  • 3.4. Market Share Analysis, 2025
  • 3.5. FPNV Positioning Matrix, 2025
  • 3.6. New Revenue Opportunities
  • 3.7. Next-Generation Business Models
  • 3.8. Industry Roadmap

4. Market Overview

  • 4.1. Introduction
  • 4.2. Industry Ecosystem & Value Chain Analysis
    • 4.2.1. Supply-Side Analysis
    • 4.2.2. Demand-Side Analysis
    • 4.2.3. Stakeholder Analysis
  • 4.3. Porter's Five Forces Analysis
  • 4.4. PESTLE Analysis
  • 4.5. Market Outlook
    • 4.5.1. Near-Term Market Outlook (0-2 Years)
    • 4.5.2. Medium-Term Market Outlook (3-5 Years)
    • 4.5.3. Long-Term Market Outlook (5-10 Years)
  • 4.6. Go-to-Market Strategy

5. Market Insights

  • 5.1. Consumer Insights & End-User Perspective
  • 5.2. Consumer Experience Benchmarking
  • 5.3. Opportunity Mapping
  • 5.4. Distribution Channel Analysis
  • 5.5. Pricing Trend Analysis
  • 5.6. Regulatory Compliance & Standards Framework
  • 5.7. ESG & Sustainability Analysis
  • 5.8. Disruption & Risk Scenarios
  • 5.9. Return on Investment & Cost-Benefit Analysis

6. Cumulative Impact of United States Tariffs 2025

7. Cumulative Impact of Artificial Intelligence 2025

8. Implantable Coronary Drug Eluting Stent Market, by Drug Type

  • 8.1. Everolimus Eluting
  • 8.2. Paclitaxel Eluting
  • 8.3. Sirolimus Eluting
  • 8.4. Zotarolimus Eluting

9. Implantable Coronary Drug Eluting Stent Market, by Generation

  • 9.1. First Generation
  • 9.2. Second Generation
  • 9.3. Third Generation

10. Implantable Coronary Drug Eluting Stent Market, by Polymer Type

  • 10.1. Biodegradable Polymer
  • 10.2. Durable Polymer
  • 10.3. Polymer Free

11. Implantable Coronary Drug Eluting Stent Market, by Stent Material

  • 11.1. Cobalt Chromium
  • 11.2. Platinum Chromium
  • 11.3. Stainless Steel

12. Implantable Coronary Drug Eluting Stent Market, by Indication

  • 12.1. Multivessel Disease
  • 12.2. Non St Elevation Myocardial Infarction
  • 12.3. St Elevation Myocardial Infarction
  • 12.4. Stable Angina

13. Implantable Coronary Drug Eluting Stent Market, by Region

  • 13.1. Americas
    • 13.1.1. North America
    • 13.1.2. Latin America
  • 13.2. Europe, Middle East & Africa
    • 13.2.1. Europe
    • 13.2.2. Middle East
    • 13.2.3. Africa
  • 13.3. Asia-Pacific

14. Implantable Coronary Drug Eluting Stent Market, by Group

  • 14.1. ASEAN
  • 14.2. GCC
  • 14.3. European Union
  • 14.4. BRICS
  • 14.5. G7
  • 14.6. NATO

15. Implantable Coronary Drug Eluting Stent Market, by Country

  • 15.1. United States
  • 15.2. Canada
  • 15.3. Mexico
  • 15.4. Brazil
  • 15.5. United Kingdom
  • 15.6. Germany
  • 15.7. France
  • 15.8. Russia
  • 15.9. Italy
  • 15.10. Spain
  • 15.11. China
  • 15.12. India
  • 15.13. Japan
  • 15.14. Australia
  • 15.15. South Korea

16. United States Implantable Coronary Drug Eluting Stent Market

17. China Implantable Coronary Drug Eluting Stent Market

18. Competitive Landscape

  • 18.1. Market Concentration Analysis, 2025
    • 18.1.1. Concentration Ratio (CR)
    • 18.1.2. Herfindahl Hirschman Index (HHI)
  • 18.2. Recent Developments & Impact Analysis, 2025
  • 18.3. Product Portfolio Analysis, 2025
  • 18.4. Benchmarking Analysis, 2025
  • 18.5. Abbott Laboratories
  • 18.6. Alvimedica Medical Technologies Inc.
  • 18.7. B. Braun Melsungen AG
  • 18.8. Biosensors International Group, Ltd.
  • 18.9. Biotronik SE & Co. KG
  • 18.10. Boston Scientific Corporation
  • 18.11. Concept Medical, Inc.
  • 18.12. Cook Medical Incorporated
  • 18.13. Hexacath S.A.S.
  • 18.14. Lepu Medical Technology (Beijing) Co., Ltd.
  • 18.15. Medinol Ltd.
  • 18.16. Medtronic plc
  • 18.17. Meril Life Sciences Pvt. Ltd.
  • 18.18. MicroPort Scientific Corporation
  • 18.19. OrbusNeich Medical Group
  • 18.20. REVA Medical, Inc.
  • 18.21. Sahajanand Medical Technologies Ltd.
  • 18.22. SINOMED Co., Ltd.
  • 18.23. Terumo Corporation
  • 18.24. Translumina GmbH

LIST OF FIGURES

  • FIGURE 1. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 2. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SHARE, BY KEY PLAYER, 2025
  • FIGURE 3. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET, FPNV POSITIONING MATRIX, 2025
  • FIGURE 4. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 5. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 6. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 7. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 8. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 9. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY REGION, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 10. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 11. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2025 VS 2026 VS 2032 (USD MILLION)
  • FIGURE 12. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • FIGURE 13. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)

LIST OF TABLES

  • TABLE 1. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 2. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 3. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 4. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 5. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY EVEROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 6. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 7. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 8. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PACLITAXEL ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 9. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 10. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 11. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SIROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 12. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 13. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 14. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ZOTAROLIMUS ELUTING, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 15. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 16. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 17. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 18. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY FIRST GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 19. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 20. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 21. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SECOND GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 22. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 23. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 24. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY THIRD GENERATION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 25. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 26. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 27. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 28. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY BIODEGRADABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 29. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 30. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 31. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DURABLE POLYMER, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 32. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 33. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 34. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER FREE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 35. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 36. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 37. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 38. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COBALT CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 39. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 40. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 41. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY PLATINUM CHROMIUM, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 42. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 43. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 44. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STAINLESS STEEL, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 45. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 46. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 47. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 48. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY MULTIVESSEL DISEASE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 49. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 50. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 51. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY NON ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 52. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 53. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 54. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY ST ELEVATION MYOCARDIAL INFARCTION, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 55. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 56. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 57. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STABLE ANGINA, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 58. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY REGION, 2018-2032 (USD MILLION)
  • TABLE 59. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 60. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 61. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 62. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 63. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 64. AMERICAS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 65. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 66. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 67. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 68. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 69. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 70. NORTH AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 71. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 72. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 73. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 74. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 75. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 76. LATIN AMERICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 77. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY SUBREGION, 2018-2032 (USD MILLION)
  • TABLE 78. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 79. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 80. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 81. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 82. EUROPE, MIDDLE EAST & AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 83. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 84. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 85. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 86. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 87. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 88. EUROPE IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 89. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 90. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 91. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 92. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 93. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 94. MIDDLE EAST IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 95. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 96. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 97. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 98. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 99. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 100. AFRICA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 101. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 102. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 103. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 104. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 105. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 106. ASIA-PACIFIC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 107. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GROUP, 2018-2032 (USD MILLION)
  • TABLE 108. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 109. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 110. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 111. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 112. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 113. ASEAN IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 114. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 115. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 116. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 117. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 118. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 119. GCC IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 120. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 121. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 122. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 123. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 124. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 125. EUROPEAN UNION IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 126. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 127. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 128. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 129. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 130. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 131. BRICS IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 132. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 133. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 134. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 135. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 136. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 137. G7 IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 138. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 139. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 140. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 141. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 142. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 143. NATO IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 144. GLOBAL IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY COUNTRY, 2018-2032 (USD MILLION)
  • TABLE 145. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 146. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 147. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 148. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 149. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 150. UNITED STATES IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)
  • TABLE 151. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, 2018-2032 (USD MILLION)
  • TABLE 152. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY DRUG TYPE, 2018-2032 (USD MILLION)
  • TABLE 153. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY GENERATION, 2018-2032 (USD MILLION)
  • TABLE 154. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY POLYMER TYPE, 2018-2032 (USD MILLION)
  • TABLE 155. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY STENT MATERIAL, 2018-2032 (USD MILLION)
  • TABLE 156. CHINA IMPLANTABLE CORONARY DRUG ELUTING STENT MARKET SIZE, BY INDICATION, 2018-2032 (USD MILLION)